$1.83
3.17% yesterday
NYSE, Nov 15, 10:00 pm CET
ISIN
US43157M1027
Symbol
HLVX
Sector
Industry

HilleVax Stock price

$1.83
+0.03 1.67% 1M
-13.27 87.88% 6M
-14.22 88.60% YTD
-12.29 87.04% 1Y
-17.26 90.41% 3Y
-17.26 90.41% 5Y
-17.26 90.41% 10Y
NYSE, Closing price Fri, Nov 15 2024
-0.06 3.17%
ISIN
US43157M1027
Symbol
HLVX
Sector
Industry

Key metrics

Market capitalization $94.13m
Enterprise Value $-70.21m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.62
P/B ratio (TTM) P/B ratio 0.51
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-135.87m
Free Cash Flow (TTM) Free Cash Flow $-113.36m
Cash position $189.31m
EPS (TTM) EPS $-3.09
P/E forward negative
Short interest 15.29%
Show more

Is HilleVax a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

HilleVax Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a HilleVax forecast:

4x Hold
100%

Analyst Opinions

4 Analysts have issued a HilleVax forecast:

Hold
100%

Financial data from HilleVax

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 3.07 3.07
17% 17%
-
-3.07 -3.07
17% 17%
-
- Selling and Administrative Expenses 24 24
33% 33%
-
- Research and Development Expense 106 106
17% 17%
-
-133 -133
18% 18%
-
- Depreciation and Amortization 3.07 3.07
17% 17%
-
EBIT (Operating Income) EBIT -136 -136
17% 17%
-
Net Profit -150 -150
39% 39%
-

In millions USD.

Don't miss a Thing! We will send you all news about HilleVax directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

HilleVax Stock News

Neutral
GlobeNewsWire
3 months ago
$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates in adults BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today...
Neutral
Accesswire
4 months ago
NEW YORK CITY, NY / ACCESSWIRE / July 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HLVX.
Neutral
Accesswire
4 months ago
NEW YORK CITY, NY / ACCESSWIRE / July 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HLVX.
More HilleVax News

Company Profile

HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.

Head office United States
CEO Robert Hershberg
Employees 90
Founded 2020
Website www.hillevax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today